It has been recently shown that COVID-19 is associated with a clinically significant coagulopathy. Several studies have indicated that elevated markers of fibrin degradation (D-dimers) in hospitalised patients are associated with poorer prognosis (death or ICU admission) (Fogarty et al., 2020, Connors and Levy, 2020). Coagulation test screening is suggested and routine thromboprophylaxis measures (including use of low molecular weight heparin) are recommended, although full anticoagulation is not yet advised in the management of such patients unless otherwise clinically indicated (Connors and Levy, 2020). We wish to draw attention to a potentially enhanced risk of thromboembolic complications in patients with psychotic disorders.
Funding
Irish Clinical Academic Training (ICAT) Programme
Wellcome Trust and the Health Research Board (Grant Number 203930/B/16/Z)
Health Service Executive National Doctors Training and Planning and the Health and Social Care, Research and Development Division, Northern Ireland
European Research Council Consolidator Award (iHEAR 724809)
History
Comments
The original article is available at https://www.sciencedirect.com/
Published Citation
Mongan D, Cannon M, Cotter DR. COVID-19, hypercoagulation and what it could mean for patients with psychotic disorders. Brain Behav Immun. 2020;88:9-10.